Viatris Retains Interest In OTC As It Spies Switch Opportunities

Viatris has penned a deal worth $2bn to offload “substantially all” of its OTC assets but has decided to retain select consumer health products and Rx-to-OTC switch candidates, including erectile dysfunction treatment Viagra.